// App-Quantinova.ai

POS0897 (2021) : REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DURING CERTOLIZUMAB PEGOL TREATMENT: 96-WEEK RESULTS FROM THE C-VIEW STUDY

Researchers

Presenter

  • I. Van der Horst-Bruinsma

Principal Investigators

  • R. Van Bentum

  • F. Verbraak

  • T. Rath

  • B. Hoepken

  • O. Irvin-Sellers

  • T. Kumke

  • L. Bauer

  • M. Rudwaleit

Medical Centers

  • Amsterdam University Medical Center, location AMC, Department of Pediatric Hematology, Amsterdam, the Netherlands

  • Academic Medical Center AMC University of Amsterdam, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands

  • St. Franziskus Hospital, Department of Ophthalmology, Muenster, Germany

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Klinikum Bielefeld, Clinic for Internal Medicine and Rheumatology, Bielefeld, Germany

  • Charité Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Berlin, Germany

Locations

  • Netherlands

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Ophthalmology (OP)

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • IV

Study Id's

  • NCT03020992

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved